Availability of Sanofi’s Nexviadyme (avalglucosidase alfa) provides NHS with new treatment for Pompe disease

8 February 2023 - Sanofi announced today that health care specialists and patients living with Pompe disease will now have ...

Read more →

Regorafenib monohydrate for patients with previously treated metastatic colorectal cancer

8 February 2023 - Regorafenib monohydrate is recommended as an option for the treatment of adults with metastatic colorectal cancer who ...

Read more →

Nivolumab in combination with fluoropyrimidine- and platinum-based chemotherapy for patients with untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma

8 February 2023 - Nivolumab, when used in combination with fluoropyrimidine-based and platinum-based combination chemotherapy, is recommended as an option ...

Read more →

The EU butts heads with big pharma to make medicines cheaper

2 February 2023 - The bloc’s pharma reform aims to get new drugs to patients faster, for less money. But it ...

Read more →

Pharma industry urges halt to further rises in record revenue clawbacks

2 February 2023 - The pharmaceutical industry is calling on the government to scrap plans to raise the statutory revenue clawback ...

Read more →

Nintedanib esylate for the treatment of adults with idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted

1 February 2023 - Nintedanib esylate is recommended as an option for the treatment of adults with idiopathic pulmonary fibrosis ...

Read more →

Somatrogon for treating growth disturbance in people 3 years and over

1 February 2023 - Somatrogon is recommended as an option for the treatment of children 3 years of age and over ...

Read more →

Upadacitinib monohydrate for the treatment of patients with active non-radiographic axial spondyloarthritis

1 February 2023 - Upadacitinib monohydrate is recommended as an option for the treatment of adults with active non-radiographic axial ...

Read more →

Jazz Pharmaceuticals receives NICE recommendation for the reimbursement of Epidyolex (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex in England

31 January 2023 - Jazz Pharmaceuticals today announced that Epidyolex (cannabidiol 100 mg/mL oral solution), developed by GW Pharmaceuticals, has been ...

Read more →

Risankizumab for the treatment of patients with previously treated moderate to severe active Crohn's disease

27 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using risankizumab in ...

Read more →

NICE approves new migraine drug for NHS use in England and Wales

25 January 2023 - Drugs regulator recommends eptinezumab for adults when three previous treatments have failed. ...

Read more →

UK's voluntary scheme for branded medicines, pricing and access (VPAS) faces a potential crisis

19 January 2023 - The UK has a “voluntary scheme for branded medicines, pricing, and access” or VPAS, which sets a ...

Read more →

NICE recommends reimbursement for Translarna

19 January 2023 - Only approved treatment for the underlying cause of nonsense mutation Duchenne muscular dystrophy. ...

Read more →

The battle over European drug pricing

19 January 2023 - UK and EU must balance health cost control with plans to grow life sciences. ...

Read more →

NICE recommends all oral triplet regimen for patients living with relapsed or refractory multiple myeloma

19 January 2023 - Since its launch in December 2017, ixazomib has been funded through the Cancer Drugs Fund and has ...

Read more →